全文获取类型
收费全文 | 287篇 |
免费 | 32篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 9篇 |
妇产科学 | 5篇 |
基础医学 | 22篇 |
临床医学 | 26篇 |
内科学 | 78篇 |
皮肤病学 | 8篇 |
神经病学 | 62篇 |
特种医学 | 1篇 |
外科学 | 24篇 |
综合类 | 7篇 |
预防医学 | 7篇 |
眼科学 | 9篇 |
药学 | 42篇 |
中国医学 | 1篇 |
肿瘤学 | 25篇 |
出版年
2024年 | 2篇 |
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 17篇 |
2020年 | 20篇 |
2019年 | 22篇 |
2018年 | 15篇 |
2017年 | 11篇 |
2016年 | 13篇 |
2015年 | 6篇 |
2014年 | 20篇 |
2013年 | 32篇 |
2012年 | 9篇 |
2011年 | 10篇 |
2010年 | 14篇 |
2009年 | 7篇 |
2008年 | 14篇 |
2007年 | 13篇 |
2006年 | 15篇 |
2005年 | 13篇 |
2004年 | 9篇 |
2003年 | 6篇 |
2002年 | 6篇 |
2001年 | 5篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 1篇 |
1991年 | 5篇 |
1990年 | 6篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1980年 | 1篇 |
排序方式: 共有326条查询结果,搜索用时 406 毫秒
81.
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. 总被引:4,自引:0,他引:4
Wolfgang H Oertel Erik Wolters Cristina Sampaio Santiago Gimenez-Roldan Bruno Bergamasco Max Dujardin Donald G Grosset Guy Arnold Klaus L Leenders Hans-Peter Hundemer Alberto Lledó Andrew Wood Paul Frewer Johannes Schwarz 《Movement disorders》2006,21(3):343-353
Dopamine agonists are used as initial treatment in patients with Parkinson's disease (PD) to reduce incidence and severity of motor complications. This paradigm is based on long-term studies, allowing "rescue" therapy with levodopa. The present strict monotherapy study (PELMOPET, the acronym for the pergolide-versus-L-dopa-monotherapy-and-positron-emission-tomography trial) evaluated the efficacy and safety of pergolide versus levodopa without levodopa "rescue" medication. This multicenter, double-blind, randomized, 3-year trial compared pergolide monotherapy (n=148) with levodopa monotherapy (n=146) in dopamine-naive patients with early PD (Hoehn and Yahr stage 1-2.5). Primary efficacy measures were clinical efficacy, severity and time to onset of motor complications, and disease progression. During the 3 years, severity of motor complications was significantly lower and time to onset of dyskinesia was significantly delayed in the group receiving pergolide (3.23 mg/day) compared with those receiving levodopa (504 mg/day). However, time to onset of motor complications was not longer in patients receiving pergolide after 3 years. Symptomatic relief (assessed by Unified Parkinson's Disease Rating Scale [UPDRS], UPDRS II, and III, Clinical Global Impressions [CGI] severity, and CGI and Patient Global Impressions [PGI] improvement) was significantly greater in patients receiving levodopa. Adverse events led to discontinuation of therapy in 17.6% of pergolide patients and 9.6% of levodopa patients. This is the first study comparing strict monotherapy with a dopamine agonist versus levodopa in previously untreated early PD. In principle, both levodopa and a dopamine agonist such as pergolide seem to be suitable options as initial PD therapy. The choice remains with the treating physician based on the different efficacy and adverse event profiles. 相似文献
82.
Yoshiaki Iwasaki Yasushi Shiratori Shuhei Hige Shuhei Nishiguchi Hitoshi Takagi Morikazu Onji Haruhiko Yoshida Namiki Izumi Yutaka Kohgo Kyosuke Yamamoto Nobuhiro Sato Akitaka Shibuya Hidetsugu Saito Michio Sata Kazuyuki Suzuki Shuichi Kaneko Mitsuhiko Moriyama Masao Omata 《Hepatology International》2009,3(3):468-479
83.
《Expert review of anti-infective therapy》2013,11(9):1055-1074
Despite great advances in antiretroviral therapy in the last decade, several limitations still remain such as adverse effects, lack of adherence and drug–drug interactions. Switching antiretroviral therapy in stable, virologically suppressed patients with the aim of improving tolerability and convenience is an expanding strategy in clinical practice. Several factors need to be taken into consideration when switching a suppressive regimen, such as previous virologic failure, genetic barrier of the new regimen, prior duration of virologic suppression and expected level of adherence. The most frequently used strategies include reductions in the number of pills, drugs or doses. Although switching strategies may be useful, not all the regimens used in clinical practice are based on data from randomized clinical trials and some may not be the best option for certain patients; therefore, therapy should be individualized taking into consideration available information as well as patient and drug characteristics. 相似文献
84.
Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy 总被引:4,自引:0,他引:4
Groselj J Guerrini R Van Oene J Lahaye M Schreiner A Schwalen S;TOP-INT- Investigators' Group 《Acta neurologica Scandinavica》2005,112(3):144-150
OBJECTIVES: To evaluate the effect of topiramate in elderly patients with onset of epilepsy after the age of 60, treatment-naive or non-responding to an initial antiepileptic drug. METHODS:Analysis of patients with epilepsy diagnosed in the preceding 5 years, aged>/=65 years (n=43), enrolled in a larger open-label trial (n=692). After titration to topiramate 100 mg/day over 4 weeks, the dose was adjusted according to individual response (maximum 400 mg/day). Patients were followed up for at least 7 months. RESULTS: After 7 months, 79% of patients remained in the study. Seizure frequency decreased significantly vs baseline (P<0.001); >/=50% reduction in seizure frequency was achieved in 87% of patients, 64% remained seizure-free. Both previously treated and naive patients responded. Fourteen per cent dropped out because of insufficient tolerability. No unexpected or unusual adverse events were observed. CONCLUSIONS: The results indicate that elderly patients respond well to topiramate monotherapy. The high patient retention rate reflects a favourable tolerability profile in this population. 相似文献
85.
Akuta N Suzuki F Suzuki Y Sezaki H Hosaka T Someya T Kobayashi M Saitoh S Arase Y Ikeda K Kobayashi M Kumada H 《Journal of medical virology》2005,75(4):550-558
The role of hepatocyte steatosis in interferon (IFN) resistance is still unclear, especially in patients infected with hepatitis C virus (HCV) genotype 2a. The present study was conducted in 364 consecutive non-cirrhotic naive patients infected with genotype 2a, who were evaluated for the severity of steatosis and response to IFN monotherapy after a 24-week median duration of therapy. The patients were examined for factors associated with steatosis and treatment efficacy according to the grade of steatosis. Early viral kinetics was also evaluated in 64 patients for predictors of response to therapy. Nine IFN-resistant patients were assessed for the relationship between amino acid sequence of HCV core region/NS5A and severity of steatosis. Multivariate analysis identified two independent factors associated with steatosis; serum ferritin > or =200 microg/l and body mass index > or =25.0 kg/m(2). The sustained virological response rate in patients with high-grade steatosis was significantly lower than in the low-grade group. Study of early viral kinetics showed a significantly lower cumulative HCV-RNA negative rate for the high-grade than low-grade steatosis group. Sequence analysis of HCV core region/NS5A in IFN-resistant patients with or without steatosis failed to identify steatosis-specific amino acid substitutions associated with resistance. This study of HCV genotype 2a suggested that steatosis is associated with excess iron storage, and that it is an important predictor of efficacy of IFN monotherapy. Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis. 相似文献
86.
M. Falcone G. Tiseo F. Iraci G. Raponi P. Goldoni D. Delle Rose I. Santino P. Carfagna R. Murri M. Fantoni C. Fontana M. Sanguinetti A. Farcomeni G. Antonelli A. Aceti C. Mastroianni M. Andreoni R. Cauda M. Venditti 《Clinical microbiology and infection》2019,21(4):474-480
Objectives
Our objective was to evaluate factors associated with recurrence in patients with 027+ and 027– Clostridium difficile infection (CDI).Methods
Patients with CDI observed between January and December 2014 in six hospitals were consecutively included in the study. The 027 ribotype was deduced by the presence of tcdB, tcdB, cdt genes and the deletion Δ117 in tcdC (Xpert® C. difficile/Epi). Recurrence was defined as a positive laboratory test result for C. difficile more than 14 days but within 8 weeks after the initial diagnosis date with reappearance of symptoms. To identify factors associated with recurrence in 027+ and 027– CDI, a multivariate analysis was performed in each patient group. Subdistributional hazard ratios (sHRs) and 95% confidence intervals (95%CIs) were calculated.Results
Overall, 238 patients with 027+ CDI and 267 with 027– CDI were analysed. On multivariate analysis metronidazole monotherapy (sHR 2.380, 95%CI 1.549–3.60, p <0.001) and immunosuppressive treatment (sHR 3.116, 95%CI 1.906–5.090, p <0.001) were factors associated with recurrence in patients with 027+ CDI. In this patient group, metronidazole monotherapy was independently associated with recurrence in both mild/moderate (sHR 1.894, 95%CI 1.051–3.410, p 0.033) and severe CDI (sHR 2.476, 95%CI 1.281–4.790, p 0.007). Conversely, non-severe disease (sHR 3.704, 95%CI 1.437–9.524, p 0.007) and absence of chronic renal failure (sHR 16.129, 95%CI 2.155–125.000, p 0.007) were associated with recurrence in 027– CDI.Conclusions
Compared to vancomycin, metronidazole monotherapy appears less effective in curing CDI without relapse in the 027+ patient group, independently of disease severity. 相似文献87.
C. Viscoli A. Cometta W. V. Kern R. De Bock M. Paesmans F. Crokaert M. P. Glauser T. Calandra 《Clinical microbiology and infection》2006,12(3):212-216
Combination therapy with a beta-lactam plus an aminoglycoside has been the standard approach for treating febrile neutropenia for many years. More recently, beta-lactam monotherapy has also been shown to be a reliable and safe approach. In the present study, 763 eligible patients with fever and neutropenia received piperacillin-tazobactam monotherapy. On day 3, according to the study protocol, 165 patients with persistent fever who fulfilled the study entry criteria were randomised to receive vancomycin or a placebo. The success rate was 51% in the intention-to-treat analysis and 62% in the per-protocol analysis. The overall mortality rate was 8% (58/763), with only 18 (2.4%) deaths attributed to the initial or subsequent infection. Randomisation had no influence on the study endpoints. The adverse event rate was evaluated only in the patient population not included in the randomised part of the study. Among these patients, adverse events probably or definitely related to piperacillin-tazobactam therapy were uncommon, confirming the favourable safety profile of piperacillin-tazobactam. It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia. 相似文献
88.
M. E. Falagas P. I. Rafailidis S. K. Kasiakou P. Hatzopoulou A. Michalopoulos 《Clinical microbiology and infection》2006,12(12):1227-1230
A retrospective cohort study evaluated the effectiveness and nephrotoxicity of intravenous colistin monotherapy vs. colistin-meropenem combination therapy for patients with multidrug-resistant Gram-negative bacterial infections. Fourteen patients received intravenous colistin monotherapy and 57 received colistin-meropenem. No significant differences were found concerning clinical response of the infection (12/14 (85.7%) vs. 39/57 (68.4%), p 0.32) and development of nephrotoxicity (0/14 (0%) vs. 4/57 (7%), p 0.58). A favourable association was revealed between survival and treatment with colistin monotherapy compared to colistin-meropenem (0/14 (0%) vs. 21/57 (36.8%) deaths, p 0.007), even after adjusting for the variables for which significant differences were found. 相似文献
89.
托吡酯与卡马西平对照治疗成人癫痫133例 总被引:3,自引:1,他引:2
目的:比较托吡酯(TPM)及卡马西平(CBZ)单药治疗新诊断的部分性发作成人癫痫患者的疗效及耐受性.方法:133例患者入组,自愿选择进入TPM组58例和CBZ组75例.起始剂量TPM 25mg·d-1,nd,CBZ100mg·d-1,bid.根据患者的发作情况及是否发生不良反应调整剂量,并充分观察该剂量下的疗效及耐受性,以达最佳或最终剂量.通过比较两组患者治疗前后的月平均发作次数变化和因不良反应退出试验的病例比例评价药物的总体疗效.结果:观察时间TPM组(8.10±6.35)个月,CBZ组(15.69±10.23)个月.最佳或最终剂量范围TPM组50~300mg·d-1,CBZ组100~600mg·d.按照发作频率减少≥50%、无效或发作增加、因不良反应退出试验分级,两组比较差异有显著性,两组总有效率分别为75.9%及68.0%(P=0.033 6),因不良反应退出比例TPM组明显低于CBZ组(1.7%vs 14.7%).结论:TPM单药治疗成年新诊断部分性发作癫痫患者的疗效与CBZ相当,安全性和耐受性明显优于CBZ. 相似文献
90.
Achilleas Attilakos Anastasia Garoufi Konstantinos Voudris Sotiria Mastroyianni Aspasia Fotinou Dimitrios T. Papadimitriou Nikolaos Gavalakis Alexia Prassouli Eustathia Katsarou 《European journal of paediatric neurology》2007,11(6):358-361
OBJECTIVE: Lipid abnormalities and thyroid dysfunction have been reported in patients treated with antiepileptic drugs. The aim of this study was to evaluate prospectively the association between thyroid and lipid profile in children treated with carbamazepine (CBZ) monotherapy. MATERIALS AND METHODS: Thyroid function was evaluated in 18 epileptic children, previously reported with CBZ-induced changes in serum lipid profile, before and at 6, 12 and 24 months of CBZ monotherapy. RESULTS: All children had normal thyroid function before the initiation of CBZ treatment. During CBZ therapy thyroid dysfunction, with increased thyrotropin (TSH) and decreased thyroxine (T4), free thyroxine (FT4) and triiodothyronine (T3) was found, while, significant association was revealed between serum low-density lipoprotein cholesterol (LDL-C) and TSH levels at 6 (r=0.469; p=0.043) and 12 (r=0.730; p=0.001) months of treatment. CONCLUSION: Lipid abnormalities may be associated with thyroid hormone disturbance in children treated with CBZ monotherapy. Since thyroid dysfunction and hypercholesterolemia are both associated with a higher atherosclerotic risk special attention and further studies are needed in epileptic patients treated with CBZ monotherapy. 相似文献